These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 2118431

  • 61. Enoxaparin (Clexane, Lovenox), a low molecular weight heparin, enhances t-PA-induced coronary thrombus lysis in anesthetized dogs without inducing hypocoagulability.
    Mestre M, Uzan A, Sedivy P, Cavero I.
    Thromb Res; 1992 May 01; 66(2-3):191-206. PubMed ID: 1329253
    [Abstract] [Full Text] [Related]

  • 62. Antithrombotic effects of MK-0852, a platelet fibrinogen receptor antagonist, in canine models of thrombosis.
    Ramjit DR, Lynch JJ, Sitko GR, Mellott MJ, Holahan MA, Stabilito II, Stranieri MT, Zhang G, Lynch RJ, Manno PD.
    J Pharmacol Exp Ther; 1993 Sep 01; 266(3):1501-11. PubMed ID: 8371153
    [Abstract] [Full Text] [Related]

  • 63. Molecular mechanism of action of newer thrombolytic agents.
    Collen D.
    J Am Coll Cardiol; 1987 Nov 01; 10(5 Suppl B):11B-15B. PubMed ID: 3117858
    [Abstract] [Full Text] [Related]

  • 64. Thrombolytic properties of human tissue-type plasminogen activator, single-chain urokinase-type plasminogen activator, and synergistic combinations in venous thrombosis models in dogs and rabbits.
    Spriggs DJ, Stassen JM, Hashimoto Y, Collen D.
    Blood; 1989 Apr 01; 73(5):1207-12. PubMed ID: 2495034
    [Abstract] [Full Text] [Related]

  • 65. Coronary thrombolysis with recombinant tissue plasminogen activator. Intracoronary vs intravenous administration.
    Gu SA, Ducas J, Wolfe K, Patton JN, Prewitt RM.
    Chest; 1991 Jul 01; 100(1):201-6. PubMed ID: 1905615
    [Abstract] [Full Text] [Related]

  • 66. Enhanced myocardial salvage by maintenance of microvascular patency following initial thrombolysis with recombinant tissue plasminogen activator.
    Longridge DJ, Follenfant MJ, Maxwell MP, Ford AJ, Hughes B.
    Cardiovasc Res; 1990 Sep 01; 24(9):697-706. PubMed ID: 2121357
    [Abstract] [Full Text] [Related]

  • 67. Double bolus administration of the novel recombinant plasminogen activator BM 06.022 improves coronary blood flow after reperfusion in a canine model of coronary thrombosis.
    Martin U, Sponer G, König R, Smolarz A, Meyer-Sabellek W, Strein K.
    Blood Coagul Fibrinolysis; 1992 Apr 01; 3(2):139-47. PubMed ID: 1606285
    [Abstract] [Full Text] [Related]

  • 68. Comparative thrombolytic properties of tissue-type plasminogen activator and of a plasminogen activator inhibitor-1-resistant glycosylation variant, in a combined arterial and venous thrombosis model in the dog.
    Collen D, Stassen JM, Yasuda T, Refino C, Paoni N, Keyt B, Roskams T, Guerrero JL, Lijnen HR, Gold HK.
    Thromb Haemost; 1994 Jul 01; 72(1):98-104. PubMed ID: 7974384
    [Abstract] [Full Text] [Related]

  • 69. Thrombolysis with intracoronary administration of YM866, a novel modified tissue-type plasminogen activator, in a canine model of coronary artery thrombosis.
    Kawasaki T, Katoh M, Kaku S, Gushima H, Takenaka T, Yui Y, Kawai C.
    Jpn J Pharmacol; 1993 Nov 01; 63(3):319-25. PubMed ID: 8107325
    [Abstract] [Full Text] [Related]

  • 70. Coronary thrombolysis with recombinant human tissue-type plasminogen activator.
    Gold HK, Fallon JT, Yasuda T, Leinbach RC, Khaw BA, Newell JB, Guerrero JL, Vislosky FM, Hoyng CF, Grossbard E.
    Circulation; 1984 Oct 01; 70(4):700-7. PubMed ID: 6541103
    [Abstract] [Full Text] [Related]

  • 71. Comparison of the bleeding potential of vampire bat salivary plasminogen activator versus tissue plasminogen activator in an experimental rabbit model.
    Montoney M, Gardell SJ, Marder VJ.
    Circulation; 1995 Mar 01; 91(5):1540-4. PubMed ID: 7867196
    [Abstract] [Full Text] [Related]

  • 72. Additional myocardial salvage by coadministration of the epoprostenol analog taprostene to recombinant single-chain urokinase-type plasminogen activator in a canine coronary thrombosis model.
    Groves R, Schneider J, Friderichs E, Giertz H, Flohé L.
    Arzneimittelforschung; 1989 Apr 01; 39(4):534-8. PubMed ID: 2665759
    [Abstract] [Full Text] [Related]

  • 73.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 74. Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis.
    Flameng W, Vanhaecke J, Stump DC, Van de Werf F, Holmes W, Guenzler WA, Flohe L, Collen D.
    J Am Coll Cardiol; 1986 Jul 01; 8(1):118-24. PubMed ID: 3086416
    [Abstract] [Full Text] [Related]

  • 75. The thrombolytic effect of miniplasmin in a canine model of femoral artery thrombosis.
    Fu J, Ren J, Zou L, Bian G, Li R, Lu Q.
    Thromb Res; 2008 Jul 01; 122(5):683-90. PubMed ID: 18328540
    [Abstract] [Full Text] [Related]

  • 76. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GPIIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation.
    Yasuda T, Gold HK, Kohmura C, Guerrero L, Yaoita H, Fallon JT, Bunting S, Collen D.
    Arterioscler Thromb; 1993 May 01; 13(5):738-47. PubMed ID: 8485125
    [Abstract] [Full Text] [Related]

  • 77. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr 01; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. Early intravenous administration of metoprolol enhances myocardial salvage by thrombolysis with recombinant tissue-type plasminogen activator after thrombotic coronary artery occlusion in the dog by improvement of the collateral blood flow to the area at risk.
    Zmudka K, Aubert A, Dubiel J, Vanhaecke J, Flameng W, Kaczmarek J, De Geest H.
    J Am Coll Cardiol; 1994 May 01; 23(6):1499-504. PubMed ID: 8176113
    [Abstract] [Full Text] [Related]

  • 80. Reversible tripeptide thrombin inhibitors as adjunctive agents to coronary thrombolysis: a comparison with heparin in a canine model of coronary artery thrombosis.
    Jackson CV, Wilson HC, Growe VG, Shuman RT, Gesellchen PD.
    J Cardiovasc Pharmacol; 1993 Apr 01; 21(4):587-94. PubMed ID: 7681904
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 12.